These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31780660)

  • 1. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma.
    Wang J; Wang J; Lopez E; Guo H; Zhang H; Liu Y; Chen Z; Huang S; Zhou S; Leeming A; Zhang RJ; Jung D; Shi H; Grundman H; Doakes D; Cui K; Jiang C; Ahmed M; Nomie K; Fang B; Wang M; Yao Y; Zhang L
    Blood Cancer J; 2019 Nov; 9(12):95. PubMed ID: 31780660
    [No Abstract]   [Full Text] [Related]  

  • 2. Velcade displays promising activity in primary effusion lymphoma cells.
    McConkey D; Nawrocki ST; Andtbacka R
    Cancer Biol Ther; 2005 Apr; 4(4):491-2. PubMed ID: 15908793
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
    Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antineoplastic effects of auranofin in canine lymphoma cells.
    Zhang H; Rose BJ; Pyuen AA; Thamm DH
    BMC Cancer; 2018 May; 18(1):522. PubMed ID: 29724201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
    Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
    Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer: survival pathways meet their end.
    McCormick F
    Nature; 2004 Mar; 428(6980):267-9. PubMed ID: 15029179
    [No Abstract]   [Full Text] [Related]  

  • 7. PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.
    Liu YY; Yao SN; Zhao Y; Yao ZH; Ma J; Xia QX; Fu K; Yang SJ
    Leuk Lymphoma; 2010 Sep; 51(9):1692-8. PubMed ID: 20807096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
    Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
    Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.
    Sachweh MC; Stafford WC; Drummond CJ; McCarthy AR; Higgins M; Campbell J; Brodin B; Arnér ES; Laín S
    Oncotarget; 2015 Jun; 6(18):16488-506. PubMed ID: 26029997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
    Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
    Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auranofin: repurposing an old drug for a golden new age.
    Roder C; Thomson MJ
    Drugs R D; 2015 Mar; 15(1):13-20. PubMed ID: 25698589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells.
    Kurosu T; Fukuda T; Miki T; Miura O
    Oncogene; 2003 Jul; 22(29):4459-68. PubMed ID: 12881702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells.
    Fingrut O; Reischer D; Rotem R; Goldin N; Altboum I; Zan-Bar I; Flescher E
    Br J Pharmacol; 2005 Nov; 146(6):800-8. PubMed ID: 16170329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma.
    Celegato M; Borghese C; Casagrande N; Mongiat M; Kahle XU; Paulitti A; Spina M; Colombatti A; Aldinucci D
    Blood; 2015 Sep; 126(11):1394-7. PubMed ID: 26228484
    [No Abstract]   [Full Text] [Related]  

  • 15. Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer.
    Kim TW; Lee SJ; Kim JT; Kim SJ; Min JK; Bae KH; Jung H; Kim BY; Lim JS; Yang Y; Yoon DY; Choe YK; Lee HG
    Oncotarget; 2016 Dec; 7(51):85332-85348. PubMed ID: 27863404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant.
    Slatter TL; Hung N; Bowie S; Campbell H; Rubio C; Speidel D; Wilson M; Baird M; Royds JA; Braithwaite AW
    Cell Death Dis; 2015 Jun; 6(6):e1783. PubMed ID: 26068791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
    Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
    Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel quinazoline HMJ-30 induces U-2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up-regulation of ATM/p53 signaling pathway.
    Chiu YJ; Hour MJ; Lu CC; Chung JG; Kuo SC; Huang WW; Chen HJ; Jin YA; Yang JS
    J Orthop Res; 2011 Sep; 29(9):1448-56. PubMed ID: 21425328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.
    Albitar L; Carter MB; Davies S; Leslie KK
    Gynecol Oncol; 2007 Jul; 106(1):94-104. PubMed ID: 17490733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.